BRGXOTCServices-Computer Programming, Data Processing, Etc.Fiscal year ends December 31
BIOREGENX, INC.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 20, 2026
$0.00+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $3.88M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Gross margin
81.1%
Operating margin
-67.1%
Net margin
-83.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -20.8% | +253.0% | – | – | |
| Gross profit | -9.3% | +229.2% | – | – |
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 39.0% | |
| Return on assets | – | – | -335.7% | |
| Current ratio | – | – | 0.06 | |
| Debt to equity | – | – | -0.26 | |
| Net debt to EBITDA | – | – | -0.95× | |
| Interest coverage | – | – | -4.2× | |
| Inventory turnover | – | – | 3.2× | |
| Capex to revenue | – | – | 0.5% | |
| Diluted shares | – | – | 960M |
Cash use needs five years of cash flow figures
Bioregenx does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-83.2%
×Asset turnover4.03×
×Equity multiplier-0.12×
=Return on equity, FY202539.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -83.2% | 4.03× | -0.12× | 39.0% |
| FY2024 | -985.2% | 3.41× | -0.25× | 845.9% |
| FY2023 | -105.5% | 7.38× | -0.20× | 156.5% |
| FY2022 | -185.7% | 0.45× | -0.07× | 6.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.54M
- Cash generatingOperating cash flow above zero$38.97K
- Return on assets improvedROA up on the prior year-2662.9% → -303.5%
- Earnings backed by cashOperating cash flow above net income$38.97K vs -$1.54M
- Less leverageLong-term debt to assets fell50.1% → 44.2%
- Better liquidityCurrent ratio rose0.08 → 0.06
- No dilutionShare count did not rise912M → 960M
- Gross margin improvedGross margin up on the prior year70.87% → 81.08%
- More efficientAsset turnover rose2.70 → 3.65